




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>G01N 15/10</b>	<b>A1</b>	(11) International Publication Number: <b>WO 97/24598</b> (43) International Publication Date: <b>10 July 1997 (10.07.97)</b>
<p>(21) International Application Number: <b>PCT/GB96/03256</b></p> <p>(22) International Filing Date: <b>27 December 1996 (27.12.96)</b></p> <p>(30) Priority Data: <b>9526684.7</b>      <b>29 December 1995 (29.12.95)</b>      <b>GB</b></p> <p>(71)(72) Applicants and Inventors: <b>SHINE, Thomas, Adam</b> [GB/US]; 190 Beacon Street, Boston, MA 02116 (US). <b>SHINE, Ian, Basil</b> [GB/US]; 444 Central Park West, New York, NY 10025 (US).</p> <p>(74) Agent: <b>GILL JENNINGS &amp; EVERY</b>; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	

(54) Title: METHOD FOR TESTING A CELL SAMPLE



(57) Abstract

In this invention, a measurement of cell permeability is determined by obtaining a measure of the volume of fluid which crosses a sample cell membrane in response to an altered environment. A lytic agent may be used to drive fluid across the cell membranes and thereby cause a change in cell volume. An alteration in osmolality of a sample suspension is preferred, in which the sample suspension is subjected to a continuous osmotic gradient.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## METHOD FOR TESTING A CELL SAMPLE

### Technical Field

5       The present invention relates to a method of measuring  
cell membrane permeability and is applicable to all types  
of cells, including red cells, white cells, platelets,  
fibroblasts, tissue cells, amoebae, fungi, bacteria, all  
eucaryotic and procaryotic cells as well as synthesized  
10 cells or particles.

### Background Art

Permeability is the passage of matter in a fluid or  
gaseous state through another material, usually in a solid  
15 state, measured as a rate or total volume transferred  
across a membrane per unit time per unit surface area at  
standard temperature and pressure. Biologically, many  
membranes, especially cell membranes, are selectively  
permeable enabling cells to transfer nutrients, hormones,  
20 gases, sugars, proteins or water across their membranes.  
This transport may be passive, depending solely upon the  
partial pressures or concentrations of the substances on  
either side of the membrane or it may be active, requiring  
energy to counter existing concentrations. Different cells  
25 have different molecule specific rates of permeability  
which are closely related to the cell's function.

Current tests of red cell permeability produce a  
single value for permeability, typically by measuring the  
30 change in concentration of a radio labelled molecule (often  
water) in or around a cell (or a population of cells).

### Disclosure of Invention

According to the present invention there is provided  
35 a new method in which a sample of cells suspended in a  
liquid medium, wherein the cells have at least one  
measurable property distinct from that of the liquid

medium, is subjected to analysis to determine a measure of cell permeability of the sample of cells by a method including the steps:

- 5 (a) passing a first aliquot of the sample cell suspension through a sensor,
- (b) measuring said at least one property of the cell suspension,
- (c) recording the measurement of said property for
- 10 the first aliquot of cells,
- (d) subjecting a second aliquot of the sample cell suspension to an alteration in at least one parameter of the cell environment which has the potential to induce a flow of fluid across the cell membranes and
- 15 thereby alter the said at least one property of the cells,
- (e) passing said second aliquot through a sensor,
- (f) measuring said at least one property of the cell suspension under the altered environment,
- 20 (g) recording the measurement of said at least one property for the second aliquot of cells,
- (h) comparing the data from steps (c) and (g) as a function of the extent of said alteration of said parameter of the cell environment and change in the
- 25 recorded measurements of said at least one property to determine a measure of cell permeability of the sample.

Blood cells travel through the entire body once a

30 minute continually transporting gases and metabolites. Blood cells also act as messengers or surrogate hormones, transmitting information around the body. It has been discovered that this peripatetic existence allows the blood cells to signal distant pathology. For example, when the

35 brain dies, when a limb has an occluded blood supply or the kidney fails to remove essential toxins, the blood cell's membrane permeability changes. Cell membrane permeability

has never been measured routinely and only rarely measured experimentally. Until now, there have been no rapid or reliable methods of performing such measurements. It has also been discovered that red cell permeability is complex, dynamically changing as molecules cross the cell's membrane depending on, for example, the shape and structure of the cell and membrane pump activity. The method of the present invention produces existing measures of permeability, but more usefully it produces more sensitive, accurate and descriptive measures of cell permeability within sixty seconds with no sample preparation.

Preferably, the property of the cells which differs from the liquid medium is one which is directly related to the volume of the cell. Such a property is electrical resistance or impedance which may be measured using conventional particle counters such as the commercially available instrument sold under the trade name Coulter Counter by Coulter Instruments Inc.. Preferably, the sensor used to detect cells and measure a change in the cells' property is that described in our co-pending International application (Agent's reference 62/2681/03). In this apparatus the cell suspension is caused to flow through an aperture where it distorts an electrical field. The response of the electrical field to the passage of the cells is recorded as a series of voltage pulses, the amplitude of each pulse being proportional to cell size.

In the preferred method of the present invention, a measurement of cell permeability is determined by obtaining a measure of the volume of fluid which crosses a sample cell membrane in response to an altered environment. The environmental parameter which is changed in the method may be any change which results in a measurable property of the cells being altered. Preferably, a lytic agent is used to drive fluid across the cell membranes and thereby cause a change in cell volume. Preferably therefore, the

environmental parameter change is an alteration in osmolality, most preferably a reduction in osmolality. Typically, the environment of the first aliquot is isotonic and thus the environment of the second aliquot is rendered  
5 hypotonic. Other suitable lytic agents include soap, alcohols, poisons, salts, and an applied shear stress.

It is possible to subject only a single aliquot of sample suspension to one or more alterations in osmolality  
10 to achieve this effect, although is preferred to use two or more different aliquots of the same sample suspension. Most preferably, the sample suspension is subjected to a continuous osmotic gradient, and in particular an osmotic gradient generated in accordance with the method of our co-  
15 pending International application (Agent's reference 80/4936/03).

In the preferred method of our co-pending International application (Agent's reference 62/2734/03),  
20 a number of measurements of particular cell parameters are made over a continuous series of osmolalities, including cell volume and cell surface area, which takes account of the deviation of the cells from spherical shape particles commonly used to calibrate the instruments. An estimate of  
25 in vivo cell shape made so that an accurate measurement of cell volume and cell surface area at all shapes is obtained. A sample suspension is fed continuously into a solution the osmolality of which is changed continuously to produce a continuous concentration gradient. Reducing the  
30 osmolality of the solution surrounding a red blood cell below a critical level causes the cell first to swell, then rupture, forming a ghost cell which slowly releases its contents, almost entirely haemoglobin, into the surrounding medium. The surface area of the each cell remains  
35 virtually unchanged on an increase in cell volume due to a reduction in osmolality of the cell's environment as the cell membrane is substantially inelastic. The time between

initiation of the alteration of the environment in each aliquot to the passage of the cells through the sensing zone is kept constant so that time is not a factor in any calculation in cell permeability. An effect of feeding the sample under test into a continuously changing osmolality gradient, is to obtain measurements which are equivalent to treating one particular cell sample with that continuously changing gradient.

10            Preferably, the measurements are recorded on a cell-by-cell basis in accordance with the method of our co-pending International application (Agent's reference 62/2734/03). The number of blood cells within each aliquot which are counted is typically at least 1000 and the cell-by-cell data is then used to produce an exact frequency distribution of cell permeability. Suitably this density can be displayed more visibly by using different colours to give a three dimensional effect, similar to that seen in radar rainfall pictures used in weather forecasting.

15            Alternatively, for a single solution of any tonicity, the measured parameter change could be displayed against a number of individual cells showing the same change. In this way a distribution of cell permeability in a tonicity of given osmolality can be obtained.

25            As discussed above, the methods in our co-pending applications can provide an accurate estimate of cell volume, or other cell parameter related to cell volume, and cell surface area over a continuous osmotic gradient for individual cells in a sample. A plot of change in cell volume against osmolality reveals a characteristic curve showing how the cell volume changes with decreasing osmolality and indicates maximum and minimum rates of flow across the membrane and the flow rates attributed to a particular or series of osmotic pressures.

30           

35

Having obtained measures of osmotic pressure ( $P_{\text{osm}}$ ), cell volume, surface area (SA) and other relevant environmental factors, it is possible to obtain a number of measures of cell permeability:

5

1) Cp rate

This coefficient of permeability measures the rate of fluid flow across a square meter of membrane in response to a specified pressure. All positive rates represent a net flow into the cell, while all negative rates are the equivalent of a net flow out of the cell. The rate is determined by:

10

$$\text{Cp rate} = \Delta \text{ cell volume} / \Delta P_{\text{osm}} / \text{SA at S.T.P.}$$

15

2) Permeability Constant  $pk_n$

This set of permeability measures describe each pressure where the net permeability rate is zero, and are numbered  $pk_0, pk_1 \dots pk_n$ .

20

(i)  $pk_0$  coincides with the minimum absolute pressure (hypotonic) to which a cell can be subjected without loss of integrity. A pressure change of one tenth of a milliosmole per kg (0.0001 atms) at  $pk_0$  produces a change in permeability of between one and two orders of magnitude making  $pk_0$  a distinct, highly reproducible measure.

25

(ii)  $pk_1$  is a measure of the cells' ability to volumetrically regulate in slightly hypotonic pressures. After a certain pressure, the cell can no longer defeat the osmotic force, resulting in a change in the cell's volume.  $pk_1$  provides a measure of the cells ability to perform this regulation, thereby measuring a cell's maximum pump transfer capability.

35



(iii)  $pk_2$ , a corollary of  $pk_1$ , is a measure of the cells ability to volumetrically regulate in hypertonic pressures, and occurs at low differential pressures, when compared to the cell's typical in vivo hydrostatic pressure.

5

The permeability constant  $pk_n$  is described by the following equation:

10 
$$pk_n = \Delta P_{osm} / SA \quad \text{at S.T.P.}$$

When calculating  $pk_0$ ,  $\Delta P_{osm}$  = (isotonic pressure) - (pressure where net flow is zero).

15

When calculating  $pk_1$ ,  $\Delta P_{osm}$  = (isotonic pressure) - (first hypotonic pressure where net positive flow begins). The calculation of  $pk_2$  is identical to  $pk_1$ , except  $\Delta P_{osm}$  measures the first hypertonic pressure where net positive flow is not zero.

20

### 3) CPA

This dimensionless value is the comparison of any two Cp rates, and is expressed as the net amount of fluid to cross the cell membrane between any two lytic concentrations. It provides a volume independent and pressure dependent comparison of permeability rates. This measure may be used to compare permeability changes in the same individual over a period ranging from minutes to months.

30

### 4) $Cp_{max}$

This is the maximum rate of flow across the cell's membrane. For almost all cells, there are two maxima, one positive (net flow into the cell) and one negative (net flow out of the cell) situated either side of  $pk_0$ .  $Cp_{max}$  is

35

determined by detecting the maximum positive and negative gradients of the continuous curve of change in cell volume against osmolality.

## 5            5)    Membrane Structural Resistance (MSR)

This is a measure of the structural forces inside a cell which resist the in-flow or out-flow of water. It is determined by the ratio of  $Cp_{max}$  to all other non-zero flow rates into the cell. As the membrane is theoretically  
 10    equally permeable at all pressures, change from the maximum flow rate outside the pressure range of  $pk_1$  to  $pk_2$  are due to mechanical forces. It is clear that  $pk_0$  is an entirely mechanical limit on the cell because as  $Cp_{rate}$  approaches  
 15    zero, MSR approaches  $\infty$ , thereby producing more strain than the membrane can tolerate.

$$MSR = Cp_{max} / Cp_{rate} \times 100\%$$

## 20           6)    Cpml

This is a measure of the physiological permeability available to an individual per unit volume of tissue or blood, or for the whole organ or total body, and is  
 25    calculated by:

$$CPml = \Delta \text{ cell volume} / \Delta P_{osm} / m^3 \text{ per ml of whole blood.}$$

30           The method of the present invention has a wide range of uses, in particular:

1.    A means of measuring permeability and permeability rates on any type of cell.
- 35    2.    A means for detecting and differentiating normal and abnormal membrane permeabilities and their causes.

3. An in vitro substitute for in vivo animal tests or human experimentation on new drugs, or toxicology experiments, and in particular the effect from unknown substances upon membrane permeability, such as nerve  
5 agents, anaesthetics, drugs, radiation and chemical warfare agents.

4. Membrane research.

10 5. Taxonomy. Different species have different membrane permeabilities which has been known but never used as a basis for taxonomy.

6. A model for other cells, particularly nerve cells,  
15 which are dependent upon membrane pumps for nerve impulse propagation.

7. In medicine for blood banking. Currently donated blood units have their shelf life limited to three weeks  
20 because some donated blood units do not survive in storage longer than this. However, the majority of units are viable for many more weeks but hospitals do not risk using a non-viable unit for transfusion. The permeability measurements of the present invention provide a means of determining the  
25 viability of blood, enabling a quick and cheap method of determining if a unit has expired. It can also be used as a basis for deciding when to discard a unit before the three week limit, thereby reducing the risk of a bad transfusion and potentially saving millions of units each  
30 year.

8. As a means for the detection of disease, diagnosis of disease, confirmation of diagnosis, monitoring prognosis of disease, monitoring treatment efficacy and monitoring  
35 remission in humans and all other species.

9. As a means of investigating pathophysiology in all species. There are many diseases that have been found to have altered cell membrane permeability that were previously unknown. For example it is altered when insulin  
5 binding to the red cell is increased as in anorexia nervosa, when anoxia induced by respiratory failure or congenital diaphragmatic hernia, or in thalassaemia intermedia, due to an undetermined mechanism. Hitherto cell permeability has never been used to monitor blood flow  
10 to a limb. One new and unexpected discovery is that occlusion of the blood flow to the lower limb sufficient to require femoral artery bypass, invariably and profoundly changes the red cell membrane permeability.

15 10. As a means for detecting and confirming death. At death, there is an alteration of cell membrane permeability that is quicker and cheaper to measure than an EEC.

20 11. Screening of routine samples for abnormality as an indication of disease.

#### Brief Description of Drawings

The present invention will now be described in detail with reference to the accompanying drawings, in which:

25

Figure 1 shows schematically an instrument used to sample and test blood cells;

30 Figure 2 shows velocity profiles for the discharge of fluids from fluid delivery syringes of a gradient generator section of the instrument of Figure 1;

Figure 3 shows a block diagram illustrating the data processing steps used in the instrument of Figure 1;

35 Figure 4 shows an example of a three-dimensional plot of osmolality against measured voltage for cells of a blood sample analyzed in accordance with the present invention;

Figure 5 shows another example of a three-dimensional plot of osmolality against measured voltage which

illustrates the frequency distribution of blood cells at intervals;

Figure 6 shows a series of three-dimensional plots for a sample tested at hourly intervals;

5        Figures 7 and 8 show results for spherical latex particles as part of an instrument calibration routine;

Figure 9 shows superimposed plots of osmolality (x-axis) against measured voltage and true volume, respectively;

10       Figures 10a to 10d show the results from the test of a healthy individual;

Figure 11 shows Price-Jones curves of the results shown in Figures 10a to 10d;

15       Figure 12 shows a graph of osmolality against cell volume and indicates a number of different measures of cell permeability;

Figure 13 shows a graph of osmolality against net fluid flow; and

20       Figure 14 shows a three-dimensional frequency distribution plot and cell parameters for an abnormal individual.

#### Detailed Description

25       Figure 1 shows schematically the arrangement of a blood sampler for use in the method of the present invention. The blood sampler comprises a sample preparation section 1, a gradient generator section 2 and a sensor section 3.

30       A whole blood sample 4 contained in a sample container acts as a sample reservoir for a sample probe 6. The sample probe 6 is connected along PTFE fluid line 26 to a diluter pump 7 via multi-position distribution valve 8 and multi-position distribution valve 9. The diluter pump 7  
35       draws saline solution from a reservoir (not shown) via port #1 of the multi-position distribution valve 9. As will be explained in detail below, the diluter pump 7 is controlled

to discharge a sample of blood together with a volume of saline into a first well 10 as part of a first dilution step in the sampling process.

5           In a second dilution step, the diluter pump 7 draws a dilute sample of blood from the first well 10 via multi-position distribution valve 11 into PTFE fluid line 12 and discharges this sample together with an additional volume of saline into a second well 13. The second well 13  
10 provides the dilute sample source for the gradient generator section 2 described in detail below.

          Instead of using whole blood, a pre-diluted sample of blood 14 in a sample container 15 may be used. In this  
15 case, a sample probe 16 is connected along PTFE fluid line 30, multi-position distribution valve 11, PTFE fluid line 12 and multi-position distribution value 9 to the diluter pump 7. In a second dilution step, the diluter pump 7 draws a volume of the pre-diluted sample 14 from the sample  
20 container 15 via fluid line 30 and multi-position distribution value 11 into fluid line 12 and discharges the sample together with an additional volume of saline into the second well 13 to provide the dilute sample source for the gradient generator section 2.

25           The gradient generator section 2 comprises a first fluid delivery syringe 17 which draws water from a supply via multi-position distribution valve 18 and discharges water to a mixing chamber 19 along PTFE fluid line 20. The  
30 gradient generator section 2 also comprises a second fluid delivery syringe 21 which draws the diluted sample of blood from the second well 13 in the sample preparation section 1 via multi-position distribution valve 22 and discharges this to the mixing chamber 19 along PTFE fluid line 23  
35 where it is mixed with the water from the first fluid delivery syringe 17. As will be explained in detail below, the rate of discharge of water from the first fluid

delivery syringe 17 and the rate of discharge of dilute blood sample from the second fluid delivery syringe 21 to the mixing chamber is controlled to produce a predetermined concentration profile of the sample suspension which exits the mixing chamber 19 along PTFE fluid line 24. Fluid line 24 is typically up to 3 metres long. A suitable gradient generator is described in detail in the Applicant's co-pending International application also filed this day (Agent's reference 62/2684/03).

10

As will also be explained in detail below, the sample suspension exits the mixing chamber 19 along fluid line 24 and enters the sensor section 3 where it passes a sensing zone 25 which detects individual cells of the sample suspension before the sample is disposed of via a number of waste outlets.

15

In a routine test, the entire system is first flushed and primed with saline, as appropriate, to clean the instrument, remove pockets of air and debris, and reduce carry-over.

20

The diluter pump 7 comprises a fluid delivery syringe driven by a stepper motor (not shown) and is typically arranged initially to draw 5 to 10ml of saline from a saline reservoir (not shown) via port #1 of multi-position distribution valve 9 into the syringe body. A suitable fluid delivery syringe and stepper motor arrangement is described in detail in the Applicant's co-pending International application also filed this day (Agents reference 80/4936/03). Port #1 of the multi-position distribution valve 9 is then closed and port #0 of both multi-position distribution valve 9 and multi-position distribution valve 8 are opened. Typically 100 $\mu$ l of whole blood is then drawn from the sample container 5 to take up the dead space in the fluid line 26. Port #0 of multi-position distribution valve 8 is then closed and any blood

25

30

35

from the whole blood sample 4 which has been drawn into a fluid line 27 is discharged by the diluter pump 7 to waste via port #1 of multi-position distribution valve 8.

5           In a first dilution step, port #0 of multi-position distribution valve 8 is opened and the diluter pump 7 draws a known volume of whole blood, typically 1 to 20  $\mu$ l, into PTFE fluid line 27. Port #0 is then closed, port #2 opened and the diluter pump 7 discharges the blood sample in fluid  
10 line 27 together with a known volume of saline in fluid line 27, typically 0.1 to 2ml, into the first well 10. Port #2 of multi-position distribution valve 8 and port #0 of multi-position distribution valve 9 are then closed.

15           Following this, port #0 of multi-position distribution valve 11 and port #3 of multi-position distribution valve 9 are opened to allow the diluter pump 7 to draw the first sample dilution held in the first well 10 to take up the dead space in PTFE fluid line 28. Port #0 of multi-  
20 position distribution valve 11 is then closed and port #1 opened to allow the diluter pump 7 to discharge any of the first sample dilution which has been drawn into fluid line 12 to waste via port #1.

25           In a second dilution step, port #0 of multi-position distribution valve 11 is re-opened and the diluter pump 7 draws a known volume, typically 1 to 20  $\mu$ l, of the first sample dilution into fluid line 12. Fluid line 12 includes a delay coil 29 which provides a reservoir to prevent the  
30 sample contaminating the diluter pump 7. Port #0 of multi-position distribution valve 11 is then closed, port #3 opened, and the diluter pump 7 then discharges the first sample dilution in fluid line 12, together with a known volume of saline, typically 0.1 to 20ml, into the second  
35 well 13. Port #3 of multi-position distribution valve 11 is then closed. At this stage, the whole blood sample has been diluted by a ratio of typically 10000:1. As will be



explained below, the instrument is arranged automatically to control the second dilution step to vary the dilution of the sample suspension to achieve a predetermined cell count to within a predetermined tolerance at the start of a test routine.

In the gradient generator section 2, the first fluid delivery syringe 17 is primed with water from a water reservoir. Port #3 of multi-position distribution valve 22 is opened and the second fluid delivery syringe draws a volume of the dilute blood sample from the second well 13 into the syringe body. Port #3 of multi-position distribution valve 22 is then closed and port #2 of both multi-position distribution valve 18 and multi-position distribution valve 22 are opened prior to the controlled discharge of water and dilute blood sample simultaneously into the mixing chamber 19.

Figure 2 shows how the velocity of the fluid discharged from each of the first and second fluid delivery syringes is varied with time to achieve a predetermined continuous gradient of osmolality of the sample suspension exiting the mixing chamber 19 along fluid line 24. The flow rate of the sample suspension is typically in the region of  $200\mu\text{l s}^{-1}$  which is maintained constant whilst measurements are being made. This feature is described in detail in the Applicant's co-pending application (Agent's reference 62/2684/01). As shown in Figure 2, a cam profile associated with a cam which drives fluid delivery syringe 21 accelerates the syringe plunger to discharge the sample at a velocity  $V_1$ , whilst a cam profile associated with a cam which drives fluid delivery syringe 17 accelerates the associated syringe plunger to discharge fluid at a lower velocity  $V_2$ . Once a constant flow rate from each delivery syringe has been established at time  $T_0$ , at time  $T_1$  the cam profile associated with fluid delivery syringe 21 causes the rate of sample discharge to decelerate linearly over

the period  $T_2-T_1$  to a velocity  $V_2$ , while simultaneously, the cam profile associated with fluid delivery syringe 17 causes the rate of fluid discharge to accelerate linearly to velocity  $V_1$ . During this period, the combined flow rate  
5 of the two syringes remains substantially constant at around  $200\mu\text{ls}^{-1}$ . Finally, the two syringes are flushed over the period  $T_3-T_2$ .

Once both the first fluid delivery syringe 17 and the  
10 second fluid delivery syringe 21 have discharged their contents, the first delivery syringe is refilled with water in preparation for the next test. If a blood sample from a different subject is to be used, the second fluid  
15 delivery syringe 21 is flushed with saline from a saline supply via port #1 of multi-position distribution valve 22 to clean the contaminated body of the syringe.

The sample suspension which exits the mixing chamber 19 passes along fluid line 24 to the sensor section 3. A  
20 suitable sensor section is described in detail in the Applicant's co-pending International application also filed this day (Agent's reference 62/2681/03). The sample suspension passes to a sensing zone 25 comprising an  
25 electrical field generated adjacent an aperture through which the individual cells of the sample suspension must pass. As individual blood cells of the sample suspension pass through the aperture the response of the electrical field to the electrical resistance of each individual cell is recorded as a voltage pulse. The amplitude of each  
30 voltage pulse together with the total number of voltage pulses for a particular interrupt period, typically 0.2 seconds, is also recorded and stored for subsequent analysis including a comparison with the osmolality of the sample suspension at that instant which is measured  
35 simultaneously. The osmolality of the sample suspension may also be determined without measurement from a knowledge of the predetermined continuous osmotic gradient generated

by the gradient generator section 2. As described below, the osmolality (pressure) is not required to determine the cell parameters.

5        Figure 3 shows how data is collected and processed. Inside each instrument is a main microprocessor which is responsible for supervising and controlling the instrument, with dedicated hardware or low-cost embedded controllers responsible for specific jobs within the instrument, such  
10    as operating diluters, valves, and stepper motors or digitizing and transferring a pulse to buffer memory. The software which runs the instrument is written in C and assembly code and is slightly less than 32 K long.

15        When a sample is being tested, the amplitude and length of each voltage pulse produced by the sensor is digitized to 12-bit precision and stored in one of two 16K buffers, along with the sum of the amplitudes, the sum of the lengths, and the number of pulses tested. Whilst the  
20    instrument is collecting data for the sensors, one buffer is filled with the digitized values while the main microprocessor empties and processes the full buffer. This processing consists of filtering out unwanted pulses, analysing the data to alter the control of the instrument  
25    and finally compressing the data before it is sent to the personal computer for complex analysis.

Optional processing performed by the instrument includes digital signal processing of each sensor pulse so  
30    as to improve filtering, improve the accuracy of the peak detection and to provide more information about the shape and size of the pulses. Such digital signal processing produces about 25 16-bit values per cell, generating about 25 megabytes of data p r test.

35

Data processing in the personal computer consists of a custom 400K program written in C and Pascal. The PC

displays and analyses the data in real time, controls the user interface (windows, menus, etc.) and stores and prints each sample.

5       The software also maintains a database of every sample tested enabling rapid comparison of any sample which has been previously tested. Additionally, the software monitors the instrument's operation to detect malfunctions and errors, such as low fluid levels, system crashes or the  
10       user forgetting to turn the instrument on.

      The voltage pulse generated by each cell of the sample suspension as it passes through the aperture of sensing zone 25 is displayed in graphical form on a VDU of a PC as  
15       a plot of osmolality against measured voltage. The sample suspension passes through the sensor section at a rate of  $200\mu\text{ls}^{-1}$ . The second dilution step is controlled to achieve an initial cell count of around 5000 cells per second, measured at the start of any test, so that in an interrupt  
20       period of 0.20 seconds, around 1000 cells are detected and measured. This is achieved by varying automatically the volume of saline discharged by the diluter pump 7 from the fluid line 12 in the second dilution step. Over a test  
25       period of 40 seconds, a total of 200 interrupt periods occur and this can be displayed as a continuous curve in a three-dimensional form to illustrate the frequency distribution of measured voltage at any particular osmolality, an example of which is shown in Figures 4 and  
5.

30

      The measured cell voltage, stored and retrieved on an individual cell basis is shown displayed on a plot of voltage against the osmolality of the solution causing that voltage change. Using individual dots to display the  
35       measured parameter change for each individual cell results in a display whereby the distribution of cells by voltage, and thereby by volume, in the population is shown for the

whole range of solutions covered by the osmolality gradient. The total effect is a three-dimensional display shown as a measured property change in terms of the amplitude of the measured voltage pulses against altered  
5 parameter, in this case the osmolality of the solution, to which the cells have been subjected and the distribution or density of the cells of particular sizes within the population subjected to the particular osmolality. The effect is to produce a display analogous to a contour map,  
10 which can be intensified by using colour to indicate the areas of greatest intensity.

When full data is available on the distribution of cell size in a particular population of cells subjected to  
15 haemolytic shock in a wide range of hypotonic solutions, at osmolalities just below a critical osmolality causing lysis a gap in the populations is visible. As shown in Figure 4, ghost cells are fully visible or identifiable in the three-dimensional plot and the unruptured cells are clearly  
20 identifiable, but between them is a region defined by osmolality and cell volume where relatively few individuals appear. The existence of this phenomenon, which we have termed the "ghost gap", has not previously been recognised.

25 If the entire series of steps are repeated at timed intervals on further aliquots of the original sample and the resulting measured voltage is plotted against osmolality, time and frequency distribution, a four-dimensional display, is obtained which may be likened to a  
30 change in weather map. This moving three-dimensional display, its motion in time being the fourth dimension, provides an additional pattern characteristic of a particular blood sample. This is shown in the series of images in Figure 6. The images shown in Figure 6 are the  
35 results of tests carried out at hourly intervals at a temperature of 37°C. As the measurements are so exact, the

repeat values are superimposable using computer sequencing techniques.

As shown, cells slowly lose their ability to function over time, but they also change in unexpected ways. The size and shape of the cells in a blood sample change in a complex, non-linear but repeatable way, repeating some of the characteristic patterns over the course of days and on successive testing. The patterns, emerging over time, show similarity among like samples and often show a characteristic wave motion. The pattern of change may vary between individuals reflecting the health of the individual, or the pattern may vary within a sample. Thus a sample that is homogeneous when first tested may split into two or several sub-populations which change with time and their existence can be detected by subjecting the sample to a wide range of different tonicities and recording the voltage pulse in the way described. As shown in Figure 6, after the first few hours the cell becomes increasingly spherical in the original sample, it then becomes flatter for several hours, then more spherical again, reaches a limit, and then becomes thinner and finally may swell again. It has been determined that the rate at which observed changes take place are influenced by pH, temperature, available energy and other factors.

The three-dimensional pattern provides data which enables identification of the precise osmolality at which particular cells reach their maximum volume, when they become spheres. With appropriate calibration, which is described in detail below, and using the magnitude of the voltage pulse, it is possible to define precisely and accurately the actual volume of such cells and thereafter derive a number of other cell parameters of clinical interest.

The amplitude of the voltage pulses produced by the sensor 25 as individual cells pass through the electrical field are proportional to the volume of each cell. However, before a conversion can be performed to provide a measure of cell volume, the instrument requires calibration. This is performed using spherical latex particles of known volume and by comparison with cell volumes determined using conventional techniques.

Experimental results have shown that the mapping of measured voltage to spherical volume of commercially available latex particles is a linear function. Accordingly, only a single size of spherical latex particles needs to be used to determine the correct conversion factor. In a first calibration step, a sample containing latex particles manufactured by Bangs Laboratories Inc. having a diameter of  $5.06\mu\text{m}$  i.e. a volume of  $67.834\text{m}^3$ , was sampled by the instrument. The three-dimensional plot for the latex particles is shown in Figure 7 with a plot of osmolality against mean voltage shown in Figure 8. In this particular test, the instrument produced a mean voltage of  $691.97\text{mV}$ . The spherical volume is given by the equation:

$$\text{Spherical volume} = \text{measured voltage} \times K_{\text{volts}}$$

where  $K_{\text{volts}}$  is the voltage conversion factor.

Re-arranging this equation gives:

30

$$K_{\text{volts}} = \frac{\text{spherical volume}}{\text{measured voltage}}$$

which in this case gives,

$$K_{\text{volts}} = \frac{67.834}{691.97} = 0.0980$$

This value of  $K_{\text{volts}}$  is only valid for the particular instrument tested and is stored in a memory within the instrument.

In a second calibration step, a shape correction factor is determined to take account of the fact that the average blood cell in the average individual has a bi-concave shape. Applying the above voltage conversion factor  $K_{\text{volts}}$  assumes that, like the latex particles, blood cells are spherical and would therefore give an incorrect cell volume for cell shapes other than spherical. In the present invention, a variable shape correction function is determined so that the mean volume of the blood cells at any osmolality up to the critical osmolality causing lysis can be calculated extremely accurately.

To illustrate this, a sample was tested at a number of accurately known osmolalities and the volume of the blood cells measured using a standard reference method, packed cell volume. A portion of the same sample was also tested by the method of the present invention using the instrument of Figure 1 to measure the voltage pulses from individual cells at the corresponding osmolalities. The results of these procedures are shown in Table 1 and plotted as two superimposed graphs of osmolality (x-axis) against measured voltage and true volume, respectively, in Figure 9.

At an isotonic osmolality of 290mosm, the true volume, as determined by the packed cell volume technique, was 92.0fl, whilst the measured mean voltage was 670mV.

The true isotonic volume of the cells is given by equation:



$$\text{Volume}_{\text{iso}} = \text{Voltage}_{\text{iso}} \times K_{\text{volts}} \times K_{\text{shape}}$$

where  $\text{Voltage}_{\text{iso}}$  is the measured voltage and  $K_{\text{shape}}$  is a shape correction factor.

5 Re-arranging:

$$K_{\text{shape}} = \frac{\text{Volume}_{\text{iso}}}{\text{Voltage}_{\text{iso}} \times K_{\text{volts}}}$$

which in this example gives,

10

$$K_{\text{shape}} = \frac{92.0}{670 \times 0.0980} = 1.4$$

15

Table 1 shows the shape correction factor  $K_{\text{shape}}$  for each of the other aliquots and demonstrates that the factor to be applied to each sample is different with the maximum shape correction being applied at isotonic osmolalities where the blood cells are bi-concave rather than spherical. To automate the calculation of  $K_{\text{shape}}$  at any osmolality of interest a shape correction function is required. The following general function describes a shape correction factor based on any two sensor readings i.e. measured voltages:

20

$$f(K_{\text{shape}}) = f(\text{SR1}, \text{SR2})$$

25

where SR1 is a sensor reading (measured voltage) at a known shape, typically spherical, and SR2 is a sensor reading (measured voltage) at an osmolality of interest, typically isotonic.

30

Analysis has shown that this is a linear function and that:

$$f(K_{\text{shape}}) = 1 + \left[ \frac{(SR1 - SR2)}{(SR1)} \right] \times K_a$$

where  $K_a$  is an apparatus dependent constant, which is determined as follows:

- 5  $K_{\text{shape}}$  at an osmolality of 290 mosm is known (see above), applying the values  $SR1 = 1432\text{mV}$ ,  $SR2 = 670\text{mV}$  and  $K_{\text{shape}} = 1.4$  to the above equation gives:

$$1.4 = 1 + \left[ \frac{(1432 - 670)}{1432} \right] \times K_a$$

- 10 re-arranging:

$$K_a = 0.7518$$

This value of  $K_a$  is constant for this instrument.

15

- The true isotonic volume of a blood sample is determined by comparing the measured voltage at an isotonic volume of interest with the measured voltage of cells of the same blood sample at some known or identifiable shape, most conveniently cells which have adopted a spherical shape, whereby:

$$\begin{aligned} \text{Volume}_{\text{iso}} &= \text{Voltage}_{\text{iso}} \times K_{\text{Volts}} \times f(K_{\text{shape}}) \\ &= SR2 \times 0.0980 \times \left[ 1 + \left[ \frac{(SR1 - SR2)}{SR1} \right] \times 0.7518 \right] \end{aligned}$$

25

In the present invention, the point at which the blood cells become spherical when subjected to a pr determined

continuous osmotic gradient can be determined very accurately. Figures 10a-10d show the results for a normal blood sample from a healthy individual. Figure 10a shows a three-dimensional plot of measured voltage against osmolality, Figure 10b shows a graph of osmolality against percentage change in measured voltage for a series of tests of a sample, Figure 10c shows the results in a tabulated form, and Figure 10d shows superimposed graphs of mean voltage and cell count for the test, respectively, against osmolality. As shown, the cell count, which is initially 5000 cells per second at the beginning of a test, reduces throughout the test due to the dilution of the sample in the gradient generator section 2. The mean voltage rises to a maximum at a critical osmolality where the blood cells achieve a spherical shape and then reduces. Using standard statistical techniques, the maxima of the curve in Figure 10b, and therefore the mean voltage at the maxima, can be determined. The mean voltage at this point gives the value SR1 for the above equation. It is then possible to select any osmolality of interest, and the associated measured voltage SR2, and calculate the true volume of the cell at that osmolality. Typically, the isotonic osmolality is chosen, corresponding to approximately 290mosm.

For the above test, at 290 mosm, SR1 = 1432mV and SR2 = 670mV. Accordingly:

$$f(K_{\text{shape}})_{290} = 1 + \left[ \frac{1432 - 670}{1432} \right] \times 0.7518$$

$$K_{\text{shape } 290} = 1.40$$

and therefore:

$$\begin{aligned} \text{Volume}_{\text{iso}} &= \text{SR2} \times K_{\text{Volts}} \times K_{\text{shape}} \\ &= 670 \times 0.0980 \times 1.40 \\ &= 91.92 \text{ fl}, \end{aligned}$$

and:

$$\begin{aligned}
 \text{Volume}_{\text{sph}} &= \text{SRl} \times K_{\text{Volts}} \times K_{\text{shape}} \\
 &= 1432 \times 0.098 \times 1.0 \\
 &= 140.34 \text{ fl.}
 \end{aligned}$$

5

Knowledge of the mean volume of the sphered cells allows calculation of spherical radius as:

$$\text{Volume}_{\text{sph}} = \frac{4\pi r^3}{3}$$

10 from which the spherical radius

$$r = \left[ \frac{3 \times \text{Volume}_{\text{sph}}}{4\pi} \right]^{\frac{1}{3}}$$

$$r = \left[ \frac{3 \times 140.34}{4\pi} \right]^{\frac{1}{3}}$$

$$= 3.22 \mu\text{m}$$

15 Having determined  $\text{volume}_{\text{iso}}$ ,  $\text{volume}_{\text{sph}}$  and the spherical cell radius, it is possible to calculate a number of other parameters. In particular:

1. Surface Area (SA)

20 Since the surface area SA is virtually unchanged at all osmolalities, the cell membrane being virtually inelastic, and in particular between spherical and isotonic, the surface area SA may be calculated by substituting  $r$  into the expression:

$$\begin{aligned} SA &= 4\pi r^2 \\ &= 4\pi \times (3.22)^2 \\ &= 130.29 \mu\text{m}^2 \end{aligned}$$

5      2.      Surface Area to Volume Ratio (SAVR)

Given that the walls of a red cell can be deformed without altering their area, once the surface area SA is known for a cell or set of cells of any particular shape, the surface area is known for any other shape, thus the surface area to volume ratio SAVR can be calculated for any volume. SAVR is given by the expression:

$$SAVR = \frac{4\pi r^2}{\text{Volume}_{iso}} = \frac{SA}{\text{Volume}_{iso}}$$

$$= \frac{130.29}{91.99}$$

$$15 = 1.42$$

### 3. Sphericity Index (SI)

The present invention can easily measure the SAVR, a widely quoted but hitherto, rarely measured indication of cell shape. For a spherical cell, it has the value of  $3/r$ , but since cells of the same shape but of different sizes may have different SAVR values, it is desirable to use the sphericity index SI which is a dimensionless unit independent of cell size, given by the expression:

$$SI = SAVR \times \frac{r}{3}$$

25

$$= 1.52$$

28

$$= 1.42 \times \frac{3.22}{3}$$

#### 4. Cell Diameter (D)

When the normal cell is in the form of a bi-concave disc at isotonic osmolality, it is known that the ratio of the radius of a sphere to that of the bi-concave disc is 0.8155. On this basis, therefore, the diameter D of a cell in the form of a bi-concave disc is given by:

$$D = \frac{2r}{0.8155}$$

$$= \frac{2 \times 3.22}{0.8155}$$

10

$$= 8.19 \mu\text{m}$$

The same parameter can be determined for all other osmolalities. The frequency distribution of the cell diameters is given both as dispersion statistics as well as a frequency distribution plot. The present invention provides an automated version of the known manual procedure of plotting a frequency distribution of isotonic cell diameters known as a Price-Jones curve. The present invention is capable of producing a Price-Jones curve of cell diameters for any shape of cell and, in particular, isotonic, spherical and ghost cells (at any osmolality) and is typically based on 250,000 cells. This is shown in Figure 10.

25

#### 5. Cell Thickness (CT)

When the cell is in the form of a bi-concave disc, an approximate measure of the cell thickness can be derived from the cross-sectional area and the volume. The area is of course derivable from the radius of the cell in spherical form. The cell thickness can therefore be calculated as follows:

$$CT = \frac{\text{Volume}_{iso}}{\pi r^2}$$

$$= \frac{91.92}{\pi \times 3.22^2}$$

$$= 2.82 \mu\text{m}$$

#### 6. Surface Area per millilitre (SAml)

The product of the surface area (SA) and the cell count (RBC) is the surface area per millilitre (SAml) available for physiological exchange. The total surface area of the proximal renal tubes that are responsible for acid-base regulation of the body fluids is  $5 \text{ m}^2$ . The total surface area of the red blood cells that also play an important part in the regulation of the acid-base balance is  $4572 \text{ m}^2$ , almost 3 orders of magnitude larger. RBC is calculated internally from a knowledge of the flow rate of the diluted blood sample, a cell count for each sample and the dilution of the original whole blood sample. Typically, RBC is approximately  $4.29 \times 10^9$  red cells per ml.

$$\begin{aligned} \text{SAml} &= \text{SA} \times \text{RBC (per ml)} \\ &= 130.29 \mu\text{m}^2 \times 4.29 \times 10^9 \\ &= 0.56 \text{ m}^2 \text{ ml}^{-1} \end{aligned}$$

### 7. Cell Permeability (Cp)

The plot of cell volume against osmolality in Figure 12 reveals a characteristic curve showing how the cell volume changes with decreasing osmolality and indicates maximum and minimum rates of flow across the membrane and the flow rates attributed to a particular or series of osmotic pressures. Many of the cell permeability measurements are primarily dependent upon the change in volume of the cells at different pressures. Table 2 shows the volume measurements produced by the method of the invention and the change in volume at each mOsm. Such a table is calculated automatically from continuous functions and is not usually seen by the user. The results are shown plotted as a graph of net fluid exchange against osmotic pressure in Figure 13.

Having obtained measures of osmotic pressure ( $P_{osm}$ ), cell volume, surface area (SA) and other relevant environmental factors, it is possible to obtain a number of measures of cell permeability:

#### a) Cp rate

This coefficient of permeability measures the rate of fluid flow across a square meter of membrane in response to a specified pressure. All positive rates represent a net flow into the cell, while all negative rates are the equivalent of a net flow out of the cell. The rate is determined by:

$$Cp \text{ rate} = \Delta \text{ cell volume} / \Delta P_{osm} / SA \text{ at S.T.P.}$$

Using the discrete values from Table 2 and Figure 13, the Cp rate between 200 and 141 mOsm is given as:

$$\begin{aligned} Cp \text{ rate}_{290,141} &= (139.94 - 93.98) / (141 - 290) / 130.29 \mu m^2 \\ &= 45.96 \text{ fl} / 149 \text{ mOsm} / 130.29 \\ &= 2.36 \times 10^{-3} \text{ fl} / \text{mOsm} / \mu m^2 \end{aligned}$$



31

$$\begin{aligned}
 &= 2.36 \times 10^9 \text{ fl/mOsm/m}^2 \\
 &= 2.36 \text{ ml/mOsm/m}^2
 \end{aligned}$$

b) Permeability Constant  $pk_n$

5

This set of permeability measures describe each pressure where the net permeability rate is zero, and are numbered  $pk_0, pk_1 \dots pk_n$ .

- 10 (i)  $pk_0$  coincides with the minimum absolute pressure (hypotonic) to which a cell can be subjected without loss of integrity and is shown in Figure 12. A pressure change of one tenth of a milliosmole per kg (0.0001 atms) at  $pk_0$  produces a change in permeability of between one and two  
15 orders of magnitude making  $pk_0$  a distinct, highly reproducible measure.

- (ii)  $pk_1$  is a measure of the cells' ability to volumetrically regulate in slightly hypotonic pressures and  
20 is also shown in Figure 12. After a certain pressure, the cell can no longer defeat the osmotic force, resulting in a change in the cell's volume.  $pk_1$  provides a measure of the cells ability to perform this regulation, thereby measuring a cell's maximum pump transfer capability.

25

- (iii)  $pk_2$ , a corollary of  $pk_1$ , is a measure of the cells ability to volumetrically regulate in hypertonic pressures, and occurs at low differential pressures, when compared to the cell's typical in vivo hydrostatic pressure (not  
30 shown).

The permeability constant  $pk_n$  is described by the following equation:

35  $pk_n = \Delta P_{osm} / SA \quad \text{at S.T.P.}$

When calculating  $pk_0$ ,  $\Delta P_{osm} = (\text{isotonic pressure}) - (\text{pressure where net flow is zero})$ .

When calculating  $pk_1$ ,  $\Delta P_{osm} = (\text{isotonic pressure}) -$   
 5 (first hypotonic pressure where net positive flow begins).  
 The calculation of  $pk_2$  (not shown) is identical to  $pk_1$ ,  
 except  $\Delta P_{osm}$  measures the first hypertonic pressure where  
 net positive flow is not zero.

10 Using the discrete values from Table 2 and Figure 13,  
 $pk_0 = 141.5 \text{ mOsm Kg}^{-1} / 130-29 \text{ } \mu\text{m}^2$   
 $= 1.086$

c) CPA

15 This dimensionless value is the comparison of any two  
 Cp rates, and is expressed as the net amount of fluid to  
 cross the cell membrane between any two pressures. It  
 provides a volume independent and pressure dependent  
 comparison of permeability rates. This measure may be used  
 20 to compare permeability changes in the same individual over  
 a period ranging from minutes to months.

From CP rate above, CP rate<sub>290.141</sub> was determined to be  
 2.41 ml/mOsm/m<sup>2</sup>.

25 CPA = (CP rate 1 - CP rate 2 / CP rate 2) x 100  
 CPA = (2.41 - 2.36) / 2.36 x 100  
 = 2.07% change

d)  $Cp_{max}$

30

This is the maximum rate of flow across the cell's  
 membrane. For almost all cells, there are two maxima, one  
 positive (net flow into the cell) and one negative (net  
 flow out of the cell) situated either side of  $pk_0$ .  $Cp_{max}$  is  
 35 determined by detecting the maximum positive and negative  
 gradients of the continuous curve of change in cell volume  
 against osmolality. From the results,  $Cp_{max}$  into the cell

is +0.670 fl/mOsm and  $Cp_{max}$  out of the cell is -0.722 fl/mOsm.

e) Membrane Structural Resistance (MSR)

5

This is a measure of the structural forces inside a cell which resist the in-flow or out-flow of water. It is determined by the ratio of  $Cp_{max}$  to all other non-zero flow rates into the cell. As the membrane is theoretically  
 10 equally permeable at all pressures, change from the maximum flow rate outside the pressure range of  $pk_1$  to  $pk_2$  are due to mechanical forces. It is clear that  $pk_0$  is an entirely mechanical limit on the cell because as  $Cp_{rate}$  approaches zero, MSR approaches  $\infty$ , thereby producing more strain than  
 15 the membrane can tolerate.

$$MSR = Cp_{max} / Cp_{rate} \times 100\%$$

f)  $Cp_{ml}$

20

This is a measure of the physiological permeability available to an individual per unit volume of tissue or blood, or for the whole organ or total body, and is calculated by:

25

$CP_{ml} = \Delta \text{ cell volume} / \Delta P_{osm} / m^3 \text{ per ml of whole blood.}$

From the above calculations, in 1 ml there are  $4.29 \times 10^9$  red cells each with a surface area of  $130.29 \mu m^2$   
 30 and  $SA_{ml} = 0.56 m^2 ml^{-1}$

At  $Cp_{max}$  (for instance) the flow rate into the cell was  
 $0.677 \text{ fl} / 130.29 \mu m^2$   
 35  $= 5.20 \times 10^{-3} \text{ fl} / \mu m^2$

Thus in 1 ml of whole blood the net volume of fluid crossing the membrane was

$$= 5.20 \times 10^{-3} \text{ fl}/\mu\text{m}^2 \times 0.559 \times 10^{12} \mu\text{m}^2/\text{ml}$$

$$= 2.91 \text{ ml/ml of whole blood}$$

5

b)  $CP_{\text{net}}$

$CP_{\text{net}}$  is defined as the rate at which fluid can be forced across a unit area of membrane at standard temperature and pressure over unit time and is a pressure independent measure of the coefficient of permeability, given by the equation:

$$CP_{\text{net}} = \frac{(\text{Volume}_{\text{sph}} - \text{Volume}_{\text{iso}})}{SA}$$

$$= \frac{140.34 - 91.92}{130.29}$$

$$= 0.372$$

$$= 3.72 \text{ ml m}^{-2}$$

15

20

25


Figure 14 illustrates the three-dimensional frequency distribution of a sample from a patient having an HbCC disease. As shown, the plot is grossly abnormal.

30

CLAIMS


1. A method of testing a sample of cells suspended in a liquid medium, wherein the cells have at least one measurable property distinct from that of the liquid medium, in which the sample is subjected to analysis to determine a measure of cell permeability of the sample of cells by a method including the steps:
- 5 (a) passing a first aliquot of the sample cell suspension through a sensor,
  - 10 (b) measuring said at least one property of the cell suspension,
  - (c) recording the measurement of said property for the first aliquot of cells,
  - 15 (d) subjecting a second aliquot of the sample cell suspension to an alteration in at least one parameter of the cell environment which has the potential to induce a flow of fluid across the cell membranes and thereby alter the said at least one property of the cells,
  - 20 (e) passing said second aliquot through a sensor,
  - (f) measuring said at least one property of the cell suspension under the altered environment,
  - (g) recording the measurement of said at least one property for the second aliquot of cells,
  - 25 (h) comparing the data from steps (c) and (g) as a function of the extent of said alteration of said parameter of the cell environment and change in the recorded measurements of said at least one property to determine a measure of cell permeability of the sample.
  - 30
2. A method according to claim 1, in which the property of the cells which differs from the liquid medium is one which is related to the volume of the cell, wherein the measurement of cell permeability is determined by obtaining a measure of the volume of fluid which crosses a sample cell membrane in response to an altered environment.
- 35

3. A method according to claim 1 or 2, in which a lytic agent is used to drive fluid across a cell membrane and thereby cause a change in cell volume.
4. A method according to any preceding claim, in which  
5 the sample suspension is subjected to a continuous osmotic gradient.
5. A method according to any preceding claim, in which the measurements are recorded on a cell-by-cell basis.
6. A method according to any preceding claim, in which  $C_p$   
10 rate is determined as a measure of cell permeability.
7. A method according to any of claims 1 to 5, in which permeability constant  $pK_n$  is determined as a measure of cell permeability, where  $n$  is a positive integer.
8. A method according to any of claims 1 to 5, in which  
15  $C_p\Delta$  is determined as a measure of cell permeability.
9. A method according to any of claims 1 to 5, in which  $C_{p_{max}}$  is determined as a measure of cell permeability.
10. A method according to any of claims 1 to 5, in which  
20 membrane structural resistance MSR is determined as a measure of cell permeability.
11. A method according to any of claims 1 to 5, in which  $C_{pml}$  is determined as a measure of cell permeability.
12. A method of determining the viability of blood held in a blood bank including the step of testing a sample of  
25 blood by the method according to any preceding claim.



2/19

Fig.2.









Fig.3.


4/19

Fig.4.



5/19

Fig.5.



6/19




Fig.6.

7/19  
Latex particles (5.06  $\mu\text{m}$ )

Fig.7.





Fig.8.



8/19

Fig.9.






Fig.10a.



9/19

Fig.10b.









11/19

Fig.10d.




12/19

Fig.11.




13/19

Fig.12.





14/19



15/19


Fig.14.

RESULTS	Value	Units	$\mu \pm 4SD$	Date
Sphering pressure	85.02	mOsm/Kg	143.70	6/4/93
Cp net	3.48	ml/m <sup>2</sup>	3.10	6/4/93
S.I.	14.5	--	17.50	6/4/93
IsoV	66.42	f1	91.00	6/4/93
SphV	96.46	f1	180.00	6/4/93



## Frequency Distributions

Dist.	mean	SD	cv	skew	kurt	n
Isotonic	16.45	7.02	43	4.0	39.9	43121
Spherical	24.39	9.76	40	1.0	1.9	2598
Ghost	19.54	6.96	36	1.1	1.5	1276



16/19

m0sm	HCT	P.C.V. true Vol (fl) (Haemolysis adj.)	Sensor mVolts (isc)	Kv sensor mv-> Vol fixed correction of 0.0980	Kshape PCV/sensor Vol	Kshape (ka=0.7518)	Sensor vol	Kshape error V.
290	38.2	92.0	670	65.7	1.40	1.40	91.93	1.00
258	41.2	98.6	678	66.4	1.48	1.40	92.75	0.94
226	44.5	105.9	756	74.1	1.43	1.35	100.38	0.95
193	49.6	116.6	933	91.4	1.28	1.26	115.39	0.99
177	52.2	122.3	1036	101.5	1.20	1.21	122.64	1.00
168	55.2	129.7	1106	108.4	1.20	1.17	126.94	0.98
161	58	136.3	1221	119.7	1.14	1.11	132.91	0.98
153	62	146.1	1349	132.2	1.11	1.04	137.96	0.94
145	61.5	147.8	1432	140.3	1.05	1.00	140.34	0.95
137	53	151.9	1380	135.2	1.12	1.03	138.93	0.91
129	31	144.5	1167	114.4	1.26	1.14	130.28	0.90
121	9.2	104.3	1052	103.1	1.01	1.20	123.66	1.19

TABLE 1

17/19

TABLE 2

	sr1	1428			
	sr2	(intr dependent)			
	ka	0.5057		CPmax	0.670
	kvolls	0.098		Cp min	-0.772
mOsm	intr	voltage (SR2)	fshape	true volume (fl)	Fluid Ex. (Δvol/mosm)
290	1	780	1.229	93.98	
289	2	790	1.226	94.91	
288	3	789	1.226	94.82	
287	4	773	1.232	93.33	
286	5	789	1.226	94.82	-0.011
285	6	787	1.227	94.63	-0.070
284	7	785	1.228	94.45	-0.051
283	8	783	1.228	94.26	-0.031
282	9	782	1.229	94.17	-0.120
281	10	780	1.229	93.98	-0.099
280	11	780	1.229	93.98	-0.072
279	12	779	1.230	93.89	-0.047
278	13	779	1.230	93.89	-0.028
277	14	778	1.230	93.79	-0.005
276	15	779	1.230	93.89	0.012
275	16	779	1.230	93.89	0.034
274	17	779	1.230	93.89	0.051
273	18	780	1.229	93.98	0.068
272	19	781	1.229	94.07	0.082
271	20	782	1.229	94.17	0.098
270	21	783	1.228	94.26	0.107
269	22	784	1.228	94.35	0.115
268	23	786	1.227	94.54	0.119
267	24	787	1.227	94.63	0.121
266	25	788	1.227	94.73	0.125
265	26	790	1.226	94.91	0.131
264	27	791	1.226	95.00	0.131
263	28	792	1.225	95.10	0.139
262	29	794	1.225	95.28	0.140
261	30	796	1.224	95.47	0.142
260	31	797	1.223	95.56	0.149
259	32	799	1.223	95.74	0.155
258	33	800	1.222	95.84	0.158
257	34	802	1.222	96.02	0.170
256	35	804	1.221	96.20	0.183
255	36	806	1.220	96.39	0.197
254	37	808	1.220	96.57	0.209
253	38	811	1.218	96.84	0.217
252	39	813	1.218	97.03	0.228
251	40	816	1.217	97.30	0.238
250	41	818	1.216	97.48	0.248
249	42	821	1.215	97.75	0.252
248	43	824	1.214	98.02	0.260
247	44	827	1.213	98.30	0.264
246	45	830	1.212	98.57	0.270
245	46	833	1.211	98.83	0.269
244	47	836	1.210	99.10	0.269
243	48	839	1.209	99.37	0.268
242	49	842	1.208	99.64	0.267
241	50	845	1.206	99.91	0.267
240	51	848	1.205	100.17	0.260
239	52	851	1.204	100.44	0.255
238	53	854	1.203	100.70	0.246
237	54	857	1.202	100.97	0.239
236	55	859	1.202	101.14	0.236
235	56	862	1.200	101.41	0.230
234	57	864	1.200	101.58	0.228
233	58	867	1.199	101.85	0.224
232	59	870	1.198	102.11	0.227
231	60	872	1.197	102.28	0.228
230	61	875	1.196	102.54	0.227
229	62	877	1.195	102.72	0.225

18/19

228	63	880	1.194	102.98	0.228
227	64	883	1.193	103.24	0.234
226	65	885	1.192	103.41	0.238
225	66	888	1.191	103.67	0.245
224	67	891	1.190	103.92	0.247
223	68	894	1.189	104.18	0.256
222	69	897	1.188	104.44	0.266
221	70	900	1.187	104.69	0.274
220	71	903	1.186	104.95	0.278
219	72	907	1.185	105.29	0.286
218	73	910	1.183	105.54	0.295
217	74	914	1.182	105.88	0.304
216	75	917	1.181	106.13	0.312
215	76	921	1.180	106.46	0.316
214	77	925	1.178	106.80	0.329
213	78	929	1.177	107.13	0.336
212	79	933	1.175	107.48	0.349
211	80	937	1.174	107.79	0.353
210	81	942	1.172	108.20	0.360
209	82	946	1.171	108.53	0.368
208	83	951	1.169	108.94	0.371
207	84	955	1.168	109.27	0.374
206	85	960	1.166	109.67	0.370
205	86	965	1.164	110.08	0.371
204	87	969	1.163	110.40	0.371
203	88	974	1.161	110.80	0.369
202	89	978	1.159	111.12	0.366
201	90	983	1.158	111.52	0.367
200	91	988	1.156	111.91	0.373
199	92	992	1.154	112.23	0.375
198	93	997	1.153	112.62	0.375
197	94	1002	1.151	113.01	0.372
196	95	1007	1.149	113.40	0.372
195	96	1012	1.147	113.79	0.374
194	97	1016	1.146	114.10	0.372
193	98	1021	1.144	114.48	0.372
192	99	1026	1.142	114.86	0.373
191	100	1031	1.141	115.24	0.380
190	101	1036	1.139	115.62	0.392
189	102	1041	1.137	116.00	0.396
188	103	1046	1.135	116.38	0.403
187	104	1052	1.133	116.82	0.416
186	105	1058	1.131	117.27	0.427
185	106	1063	1.129	117.84	0.441
184	107	1069	1.127	118.08	0.454
183	108	1076	1.125	118.59	0.465
182	109	1082	1.123	119.03	0.481
181	110	1089	1.120	119.53	0.501
180	111	1096	1.118	120.04	0.510
179	112	1103	1.115	120.53	0.519
178	113	1111	1.112	121.10	0.529
177	114	1119	1.109	121.86	0.535
176	115	1126	1.107	122.15	0.539
175	116	1134	1.104	122.70	0.540
174	117	1142	1.101	123.25	0.538
173	118	1150	1.098	123.80	0.542
172	119	1158	1.096	124.33	0.545
171	120	1166	1.093	124.87	0.547
170	121	1174	1.090	125.40	0.551
169	122	1183	1.087	125.99	0.556
168	123	1191	1.084	126.51	0.565
167	124	1200	1.081	127.10	0.575
166	125	1209	1.078	127.67	0.586
165	126	1218	1.074	128.24	0.597
164	127	1228	1.071	128.87	0.613
163	128	1238	1.067	129.49	0.624
162	129	1248	1.064	130.10	0.638
161	130	1259	1.060	130.77	0.651
160	131	1270	1.056	131.42	0.661
159	132	1281	1.052	132.07	0.669



19/19

158	133	1293	1.048	132.77	0.670	CP max
157	134	1305	1.044	133.46	0.666	
156	135	1317	1.039	134.14	0.658	
155	136	1329	1.035	134.81	0.642	
154	137	1340	1.031	135.41	0.622	
153	138	1352	1.027	136.06	0.596	
152	139	1363	1.023	136.65	0.564	
151	140	1373	1.019	137.17	0.530	
150	141	1384	1.016	137.75	0.490	
149	142	1393	1.012	138.21	0.441	
148	143	1401	1.010	138.61	0.391	
147	144	1409	1.007	139.01	0.338	
146	145	1415	1.005	139.31	0.278	
145	146	1420	1.003	139.55	0.219	
144	147	1424	1.001	139.75	0.156	
143	148	1427	1.000	139.90	0.089	
142	149	1428	1.000	139.94	0.021	pk0
141	150	1428	1.000	139.94	-0.049	pk0
140	151	1426	1.001	139.85	-0.120	
139	152	1423	1.002	139.70	-0.188	
138	153	1418	1.004	139.46	-0.253	
137	154	1412	1.006	139.16	-0.316	
136	155	1405	1.008	138.81	-0.375	
135	156	1397	1.011	138.41	-0.434	
134	157	1388	1.014	137.95	-0.487	
133	158	1378	1.018	137.44	-0.536	
132	159	1367	1.022	136.86	-0.582	
131	160	1355	1.026	136.22	-0.619	
130	161	1343	1.030	135.58	-0.652	
129	162	1331	1.034	134.92	-0.675	
128	163	1318	1.039	134.20	-0.695	
127	164	1306	1.043	133.52	-0.708	
126	165	1293	1.048	132.77	-0.718	
125	166	1281	1.052	132.07	-0.722	CP min
124	167	1268	1.057	131.30	-0.719	
123	168	1256	1.061	130.59	-0.716	
122	169	1244	1.065	129.86	-0.709	
121	170	1233	1.069	129.18	-0.701	
120	171	1222	1.073	128.49	-0.689	
119	172	1211	1.077	127.80	-0.681	
118	173	1200	1.081	127.10	-0.669	
117	174	1190	1.084	126.45	-0.654	
116	175	1180	1.088	125.80	-0.633	
115	176	1170	1.091	125.14	-0.611	
114	177	1161	1.095	124.54	-0.590	
113	178	1153	1.097	124.00	-0.569	
112	179	1145	1.100	123.46	-0.544	
111	180	1137	1.103	122.91	-0.517	
110	181	1129	1.106	122.36	-0.494	
109	182	1122	1.108	121.87	-0.470	
108	183	1116	1.110	121.45	-0.443	
107	184	1110	1.113	121.03	-0.412	
106	185	1104	1.115	120.61	-0.381	
105	186	1099	1.117	120.25	-0.351	
104	187	1094	1.118	119.89	-0.321	
103	188	1090	1.120	119.61	-0.292	
102	189	1086	1.121	119.32	-0.260	
101	190	1083	1.122	119.10	-0.228	
100	191	1080	1.123	118.88	-0.193	
99	192	1077	1.124	118.67	-0.118	
98	193	1075	1.125	118.52	-0.179	
97	194	1074	1.125	118.45	-0.261	
96	195	1073	1.126	118.37	-0.239	
95	196	1081	1.123	118.96	-0.539	
94	197	1055	1.132	117.05	-0.638	
93	198	1047	1.135	116.45	-0.772	
92	199	1062	1.130	117.57		
91	200	997	1.153	112.62		

# INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/GB 96/03256

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 G01N15/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 3 502 412 A (BURNS DONALD A) 24 March 1970 see page 1 see column 3, line 14 - column 4, line 17 ---	1
A	US 4 271 001 A (IMAFUKU HIROSHI ET AL) 2 June 1981 see column 1, line 5-18 see column 1, line 25-43 see column 3, line 17-42; figure 1 ---	1
A	US 4 081 340 A (ZIMMERMANN ULRICH ET AL) 28 March 1978 see abstract; figure 1 ---	1
A	US 4 240 027 A (JACOBI JOHN H ET AL) 16 December 1980 see abstract ---	1
-/-		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

30 May 1997

Date of mailing of the international search report

06.06.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Zinngrebe, U

# INTERNATIONAL SEARCH REPORT

Int. onal Application No

PCT/GB 96/03256

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>EP 0 595 352 A (MICRO MED INC) 4 May 1994 see abstract</p> <p>-----</p>	1

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/GB 96/03256

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 3502412 A	24-03-70	DE 1802671 A FR 1588689 A GB 1253665 A	16-10-69 17-04-70 17-11-71
US 4271001 A	02-06-81	JP 1405790 C JP 55117956 A JP 62015137 B JP 54125885 A DE 2911033 A FR 2420763 A GB 2019001 A,B	27-10-87 10-09-80 06-04-87 29-09-79 04-10-79 19-10-79 24-10-79
US 4081340 A	28-03-78	DE 2405119 A FR 2259904 A GB 1481480 A JP 1171030 C JP 50107181 A JP 58004550 B US 4154668 A	04-09-75 29-08-75 27-07-77 17-10-83 23-08-75 26-01-83 15-05-79
US 4240027 A	16-12-80	NONE	
EP 0595352 A	04-05-94	US 5610027 A AU 676498 B AU 5031793 A CA 2109045 A CN 1093167 A JP 6201686 A US 5532139 A	11-03-97 13-03-97 12-05-94 01-05-94 05-10-94 22-07-94 02-07-96